866-997-4948(US-Canada Toll Free)

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Jun 2013

Category :

Diabetes

No. of Pages : 41 Pages


Global Markets Directs, Diabetic Peripheral Neuropathy - Pipeline Review, H1 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy. 

Diabetic Peripheral Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Peripheral Neuropathy.
  • A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Peripheral Neuropathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Diabetic Peripheral Neuropathy 7
Diabetic Peripheral Neuropathy Therapeutics under Development by Companies 9
Diabetic Peripheral Neuropathy Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Diabetic Peripheral Neuropathy Therapeutics Products under Development by Companies 14
Diabetic Peripheral Neuropathy Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Diabetic Peripheral Neuropathy Therapeutics Development 16
Viromed Co., Ltd. 16
Cebix Incorporated 17
Diabetic Peripheral Neuropathy Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
VM-202 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MTP-131 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CBX-129801 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Compounds For Peripheral Neuropathy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NMIA-001 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Diabetic Peripheral Neuropathy Therapeutics Drug Profile Updates 32
Diabetic Peripheral Neuropathy Therapeutics - Dormant Products 36
Diabetic Peripheral Neuropathy Product Development Milestones 37
Featured News & Press Releases 37
Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin 37
Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 37
Jun 09, 2012: Cebixs Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 38
May 04, 2012: Pfizer Reports Top-Line Results From Phase III Trial Of Lyrica Capsules CV In Patients With Diabetic Peripheral Neuropathy 38
Feb 21, 2012: SK Biopharmaceuticals Initiates Phase II Trials In US 39

Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Table


Number of Products Under Development for Diabetic Peripheral Neuropathy, H1 2013 7
Products under Development for Diabetic Peripheral Neuropathy Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Viromed Co., Ltd., H1 2013 16
Cebix Incorporated, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Diabetic Peripheral Neuropathy Therapeutics Drug Profile Updates 32
Diabetic Peripheral Neuropathy Therapeutics Dormant Products 36

List of Chart


Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2013 7
Products under Development for Diabetic Peripheral Neuropathy Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *